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IgG1 Fc N-glycan galactosylation as 
a biomarker for immune activation
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Erika von Mutius8,9, André C. Knulst10, Jon Genuneit11, Philip J. Cooper7,12, Cornelis H. Hokke13, 
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Immunoglobulin G (IgG) Fc N-glycosylation affects antibody-mediated effector functions and varies 
with inflammation rooted in both communicable and non-communicable diseases. Worldwide, 
communicable and non-communicable diseases tend to segregate geographically. Therefore, we 
studied whether IgG Fc N-glycosylation varies in populations with different environmental exposures 
in different parts of the world. IgG Fc N-glycosylation was analysed in serum/plasma of 700 school-age 
children from different communities of Gabon, Ghana, Ecuador, the Netherlands and Germany. IgG1 
galactosylation levels were generally higher in more affluent countries and in more urban communities. 
High IgG1 galactosylation levels correlated with low total IgE levels, low C-reactive protein levels and 
low prevalence of parasitic infections. Linear mixed modelling showed that only positivity for parasitic 
infections was a significant predictor of reduced IgG1 galactosylation levels. That IgG1 galactosylation 
is a predictor of immune activation is supported by the observation that asthmatic children seemed to 
have reduced IgG1 galactosylation levels as well. This indicates that IgG1 galactosylation levels could 
be used as a biomarker for immune activation of populations, providing a valuable tool for studies 
examining the epidemiological transition from communicable to non-communicable diseases.
Antibodies are glycoproteins, and the N-glycans of immunoglobin G (IgG) can show considerable variation in 
structure, with additions of fucose, N-acetylglucosamine (GlcNAc), galactose and/or sialic acid to a common core 
(Fig. 1). Patterns in IgG Fc N-glycosylation have been found to vary with numerous physiological and pathogenic 
conditions, such as with age, sex, pregnancy, and certain infectious diseases, chronic inflammatory diseases, and 
cancers1–5. Although these associations are not well understood, it is known that certain changes in IgG glyco-
sylation can affect antibody-mediated effector functions. It has also been shown that stimuli received during 
activation and differentiation of B cells could result in changes in glycosylation of the antibodies produced6. 
Furthermore, in vivo glycosylation changes of antigen-specific IgG1 were observed after vaccination7. These stud-
ies indicate that antibody glycosylation could represent a valuable readout for immunological status.
Disease patterns are changing worldwide; in affluent countries, the prevalence of communicable infectious 
diseases has declined, while those of non-communicable chronic inflammatory diseases have increased substan-
tially8. Developing countries are still at the forefront of this transition, with large differences in prevalences of 
communicable and non-communicable diseases in rural and urban areas. The mechanisms underlying these dis-
eases may be rather different. Infections are often associated with strong inflammatory responses resulting from 
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activation of immune cells by pathogen-associated molecular patterns and foreign antigens9. At the same time, 
many non-communicable diseases that are seen in affluent countries or upon urbanisation are also associated 
with tissue inflammation. These diseases might result from triggering of the immune system by a different array 
of stimuli such as damage-associated molecular patterns, self-antigens, and/or allergens10.
This raises the question how IgG glycosylation patterns differ with infection pressure and with affluence and 
urbanisation. It is possible that IgG glycosylation patterns could provide a biomarker of immune activation in the 
context of urbanisation, which is a much needed tool for epidemiological studies.
Results
Study populations. The study was conducted among 700 school-aged children from urban and rural 
communities in Gabon, Ghana, Ecuador, the Netherlands and Germany. The study groups showed considerable 
heterogeneity in factors such as weight, height, prevalence of parasitic infections and urbanisation (Table 1).
IgG glycosylation pattern. IgG1 galactosylation levels in children appeared to follow a developing 
country-affluent country gradient and a rural-urban gradient, with higher levels of IgG1 galactosylation in 
Figure 1. IgG1 with heavy chains in blue, light chains in purple and glycans, attached to Asn-297 of both 
Fc chains, in red. Examples of IgG Fc N-glycan structures are shown on the right. They can differ by additions 
of galactose (G), fucose (F), bisecting N-acetylglucosamine (GlcNAc, N) and/or sialic acid (S). The left figure 
was adapted from Arnold et al.3 and reproduced with permission of Prof. Dwek and Annual Reviews in the 
format Republish in a journal/magazine via Copyright Clearance Center. Glycan structures were drawn with 
GlycoWorkbench44.
Population n Age (range)
Male 
sex Weight zBMIa Schistosomiasis STH Malaria
GAB
PK Rural 16 9.0 (7–11) 33.3% 22 100.0% 87.5% 37.5%
LA Semi-urban 23 8.0 (7–12) 34.8% 28 17.4% 13.0% 13.0%
GHA
AD Rural 68 10.0 (5–14) 45.6% 25 −0.68 50.8% 33.8% 58.3%
MA Rural 87 10.0 (5–14) 55.2% 27 −0.80 30.1% 19.7% 44.9%
JT Urban,  low SES 87 10.0 (6–17) 66.3% 27 −1.16 0.0% 17.1% 0.0%
UP Urban,  high SES 81 9.0 (5–13) 53.2% 43
b 0.65b 0.0% 3.4% 6.7%
ECU
TA Rural 31 9.0 (8–12) 51.6% 26.6 −0.43 93.5%
LP Rural 30 10.5 (8–12) 36.7% 28.6 −0.08 66.7%
SA Rural 35 10.0 (8–12) 57.1% 29.0 −0.60 68.6%
BZ Rural 24 10.0 (8–12) 58.3% 28.6 0.23 50.0%
ZG Rural 32 11.0 (8–12) 50.0% 31.6 −0.14 71.9%
TR Rural 18 11.0 (8–12) 66.7% 30.1 −0.48 27.8%
PO Rural 23 9.0 (8–12) 56.5% 27.0 −1.91 4.3%
NLD Urban and semi-urban 20 9.5(8–12) 60.0%
DEU
Healthy
Rural 100 8.0 (6–11) 40.0% 30.1 0.45
Urban 25 9.0 (9–10) 60.0% 39.0b 0.06b
Asthmaticc
Rural 49 9.0 (6–11) 61.2% 29.6 0.21
Urban 24 9.0 (9–10) 66.7% 33.3b 0.09b
Table 1.  Characteristics of the study populations. Values represent medians (min-max), percentage male 
or prevalence. Age is shown in years and weight in kg. aAge-standardised z-scores for body mass index (BMI) 
according to the WHO Reference40. bInformation was available for < 50% of participants. cAsthmatic children 
were only included in the comparison of healthy and asthmatic Germans as in Fig. 4. For the other analyses, 
only healthy Germans were included. STH = soil-transmitted helminth infected, GAB = Gabon, GHA = Ghana, 
ECU = Ecuador, DEU = Germany, NLD = the Netherlands, SES = socioeconomic status.
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children from more affluent countries and from more urban communities (Fig. 2a). Thus, IgG1 galactosylation 
levels were higher in children from the high-income countries Germany and the Netherlands than in children 
from the lower-income countries Gabon, Ghana and Ecuador. Furthermore, in countries where rural to urban 
communities could be studied (Gabon, Ghana and Germany), IgG1 galactosylation levels were higher in urban as 
compared to rural children (Supplementary Table S1-2). In Ghana, the galactosylation levels were not only com-
pared between urban and rural children, but also amongst urban children: a group of children was from a school 
that served high socioeconomic status families, while another group was from a school that served low socioeco-
nomic families. The galactosylation levels were highest in children from UP (University of Ghana Primary School 
Legon) (urban, high socioeconomic status) and lowest in children from rural Ayikai Doblo (AD). Children from 
rural Mayera (MA) and from Jamestown (JT) (urban, low socioeconomic status) had intermediate levels.
Regarding other forms of glycosylation, the gradient for IgG1 sialylation largely followed the gradient for 
IgG1 galactosylation when comparing communities within countries, with higher sialylation levels in more 
urban communities (Supplementary Fig. S1A). This association is expected, as sialic acid is added to galactose, 
and therefore, galactosylation is required for sialylation. However, when considering the number of sialic acids 
per galactose moiety (SA/Gal), the order of groups was roughly reversed, with a higher SA/Gal ratio in more 
rural communities (Supplementary Fig. S1B). A rural-urban gradient could be present for IgG1 fucosylation, 
as fucosylation levels were relatively low in the rural Ghanaian communities and both Gabonese communities 
(Supplementary Fig. S1C). There was no clear pattern for bisecting GlcNAc (Supplementary Fig. S1D), as is also 
reflected by an absent correlation with galactosylation (Supplementary Table S4).
Glycosylation patterns of IgG2 and IgG4 correlated with those of IgG1 (Supplementary Fig. S2, Supplementary 
Table S5). However, IgG4 levels were too low in many samples from the Netherlands and Germany to allow anal-
ysis of glycosylation patterns.
Correlation between IgG1 galactosylation and markers of inflammation and immune activa-
tion. The rural-urban gradient of IgG1 galactosylation was further studied in relation to the acute-phase 
C-reactive protein (CRP) as a marker of inflammation. Overall, CRP levels, amongst the studied communities, 
were in the reverse order of IgG1 galactosylation levels (Fig. 2b). Children from Germany and the Netherlands 
had the highest levels of IgG1 galactosylation and the lowest levels of CRP, while children from Gabon and Ghana 
had the lowest levels of IgG1 galactosylation and the highest levels of CRP. A significant, albeit weak, negative 
correlation was found between IgG1 galactosylation and CRP levels (Supplementary Fig. S3A).
A negative correlation was also found between IgG1 galactosylation and total IgE levels, which is associated 
with activation of the immune system as seen with allergy and parasitic infections (Supplementary Fig. S3B)11. 
Children from Germany and the Netherlands had the lowest levels of total IgE and highest levels of IgG1 galacto-
sylation. Communities within countries followed a rural-urban pattern with high levels of IgE in rural communi-
ties and low levels in urban communities (Fig. 2c).
IgG1 galactosylation can be predicted by parasitic infections. Samples from Ecuador provided the 
opportunity to disentangle the relative contribution of infections or other factors associated with urbanisation 
to IgG1 galactosylation levels. In Ecuador, all of the 7 communities studied were rural, but within the rural com-
munities the degree of urbanisation of the communities was assessed by measuring infrastructure, socioeconom-
ics, and lifestyle at community level (definitions in Supplementary Table S6)12. A low galactosylation level was 
Figure 2. (a) IgG1 galactosylation, (b) CRP levels and (c) total IgE levels compared between various 
communities and countries. Boxplots have 10–90% whiskers. The world map was based on a figure from 
Wikimedia Commons and modified using Adobe Illustrator CC 2014 (Adobe Systems Inc., San Jose, CA, USA).
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significantly correlated with (a) the presence of a telephone system, and high proportions of (b) soil-transmitted 
helminth (STH) infections, (c) households with a pet dog, and (d) crowded households (Fig. 3a).
As parasite prevalence data, not only for STH (encompassing hookworm, roundworm, whipworm and/or 
threadworm) but also schistosomiasis and malaria, were available for Ghanaian and Gabonese children as well, 
correlations between parasitic infections and IgG1 galactosylation could be assessed beyond Ecuador. In Ghana, 
positivity for malaria, schistosomiasis or STHs was negatively correlated with IgG1 galactosylation, but although 
significant, this was a weak correlation (Fig. 3b). In Gabon, a moderate negative correlation with positivity for 
schistosomiasis was found, but no correlation with malaria or STHs, which might be due to low statistical power. 
Taken together, parasitic infections are correlated with lower levels of IgG1 galactosylation in Ecuador, in Ghana, 
and in Gabon. Therefore, the differences in IgG1 galactosylation between countries and communities could be 
driven by immune activation due to infectious agents, such as micro-organisms and parasites.
To further investigate this hypothesis, linear mixed (multi-level) modelling was used to describe IgG1 galacto-
sylation for all communities from all countries, as shown in Table 2. This modelling approach allowed clustering 
of communities, thereby taking community effects into account (irrespective of country). STH infection was a 
significant negative predictor of IgG1 galactosylation, and schistosomiasis and CRP level near-significant predic-
tors. IgE level was not a significant predictor, as the variation was already explained for by parasitic infections. Age 
and sex were irrelevant predictors for this study population, likely because of the low and small age range. Thus, 
this modelling approach shows that parasitic infections, which are strong inducers of immune activation, could 
explain differences in IgG1 galactosylation.
IgG1 galactosylation and immune activation. To assess whether the association between IgG1 galac-
tosylation and parasitic infections can be generalised to immune activation, we analysed samples from subjects 
from a rural and urban community in Germany classified as being asthmatic or not. In both areas, the asthmatic 
children had higher levels of total IgE than healthy children (Fig. 4). In line with the concept that immune acti-
vation in general appears to be associated with lower IgG1 galactosylation, in both communities, children with 
asthma showed a tendency for lower levels of IgG1 galactosylation than healthy controls.
Discussion
Glycosylation of antibodies is known to vary with numerous physiological and pathological conditions. This 
study shows that galactosylation of IgG1 Fc N-glycans varies considerably between affluent and developing coun-
tries and also between urban and rural communities in the same country, where lower galactosylation levels are 
seen in less affluent countries and in more rural communities. Regarding factors that could explain this pattern, 
when considering all study participants, a negative correlation was found between CRP levels, a marker of inflam-
mation, and IgG1 galactosylation levels. Moreover, total IgE levels, a marker of immune activation associated 
with parasitic helminth infections and allergy, were also negatively associated with IgG1 galactosylation levels. 
Although rural-urban differences could be explained by exposure to microorganisms and parasites, lifestyle and 
Figure 3. (a) Spearman’s correlation between median IgG1 galactosylation and factors associated with 
infrastructure, socioeconomics and lifestyle amongst Ecuadorian communities. Definitions of the variables are 
listed in Supplementary Table S6. Correlations are based on community data (n = 7). (b) Spearman’s correlation 
between IgG1 galactosylation and parasite infection status per individual, in Ecuador, Ghana and Gabon. 
Shown are Spearman’s rho correlation coefficient (rs) values with corresponding 95% confidence intervals.
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environmental difference could also play a role. We had data available from Ecuadorian rural communities, where 
information on infrastructure, socioeconomic and lifestyle measures was available in addition to parasitic infec-
tions. The data supported the contribution of infections, as IgG1 galactosylation was inversely correlated with the 
percentage of STH infections, pet dogs, and household crowding, but not with other factors related to urbanisation 
such as housing characteristics or education level of the parents. Parasitic infections, not only STHs but also 
schistosomiasis and malaria, were also found to be inversely correlated with galactosylation among Ghanaian and 
Gabonese children. Finally, linear mixed (multi-level) modelling of all communities from all countries in a single 
model confirmed that parasitic infections explained the IgG1 galactosylation pattern best.
Although decreased IgG1 galactosylation was best explained by parasitic infections in our study, this could 
perhaps be generalised to immune activation. During life, people are continuously challenged with antigens, and 
the number of experienced immune activations will increase with age. Thus, the hypothesis that low levels of IgG1 
galactosylation are associated with immune activation is supported by the notion of decreased IgG1 galactosyla-
tion levels with increasing age2,13. Also acute systemic inflammation and chronic inflammatory conditions have 
been shown to be associated with glycosylation changes14–16. In line with this, our study shows a similar pattern 
where children with asthma tend to have lower IgG galactosylation levels as well. Given the rural-urban pattern of 
IgG galactosylation levels, the pattern seen with CRP, total IgE, parasitic infections and children with and without 
asthma, we propose that reduced IgG1 galactosylation is a biomarker of immune activation.
The mechanism behind altered IgG glycosylation is not fully understood. With respect to galactosylation, one 
possibility is that, in the face of increasing amounts of IgG1 produced by a single plasma B cell, an insufficient 
capacity of galactosyltransferases leads to lower galactosylation. However, it is known that upon vaccination both 
galactosylation of antigen-specific IgG1 and antibody titres increase7, while for rheumatoid arthritis IgG titres 
Model Effects Parameter b P value 95% CI
Starting model
Fixed
Intercept 47.64 < 0.001 43.44 51.84
Sex 0.68 0.155 − 0.26 1.61
Age − 0.06 0.670 − 0.33 0.21
Log(CRP level) − 0.66 0.068 − 1.37 0.05
Log(Total IgE level) − 0.11 0.787 − 0.92 0.69
Schistosomiasis − 2.41 0.024 − 4.50 − 0.32
STH infection − 1.24 0.059 − 2.53 0.05
Random
Residual 30.29 < 0.001 26.88 34.15
Intercept (Community) 5.55 0.052 2.02 15.21
Final model 
Fixed
Intercept 48.62 < 0.001 46.82 50.43
STH infection − 1.37 0.028 − 2.58 − 0.15
Random
Residual 30.99 < 0.001 27.73 34.63
Intercept (Community) 8.47 0.019 3.68 19.51
Table 2.  The starting linear mixed (multi-level) model with IgG1 galactosylation as dependent variable 
is shown, as well as the final model after sequential removal of total IgE level, age, sex, CRP level, and 
schistosomiasis status as non-significant fixed effects. The fixed-effect and random-effect/covariance 
estimates (b) for each parameter are given with the corresponding t-test P values and 95% confidence intervals. 
b indicates whether a relationship between the parameter and IgG1 galactosylation is positive or negative.
Figure 4. (a) IgG1 galactosylation and (b) total IgE levels in rural and urban German children, with and 
without asthma. P values as determined by Mann-Witney U tests are indicated. Boxplots have 10–90% whiskers.
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and galactosylation are not associated4. Therefore, the IgG galactosylation level differences are probably not sim-
ply a by-product of hyperactive antibody production.
Another possibility is that IgG galactosylation changes are induced by (micro-)environmental factors that 
influence B cell activation. Such factors could reduce the activity of enzymes such as glycosyltransferase17, or 
favour expansion of B cell populations producing antibodies with specific glycosylation profiles6,18. A study 
by Wang et al. has shown that CpG oligodeoxynucleotide, interleukin-21, and interferon-γ increase galacto-
sylation and CpG oligodeoxynucleotide and interleukin-21 increase sialylation, while all-trans retinoic acid (a 
natural metabolite of vitamin A) decreases galactosylation and sialylation levels6. Therefore, different environ-
mental exposures such as pathogens might be responsible for the lower levels of galactosylation in our rural study 
participants.
In terms of functional consequences, low IgG galactosylation levels are associated with several inflammatory 
diseases, such as rheumatoid arthritis, juvenile onset chronic arthritis, systemic lupus erythematosus, multiple 
sclerosis, Crohn’s disease, tuberculosis and leishmaniasis4,19–23. In contrast, increased galactosylation is seen dur-
ing pregnancy, and in rheumatoid arthritis patients who experience pregnancy-induced remission5,24. This sug-
gests that increased galactosylation of antibodies might be functionally more anti-inflammatory25. Karsten et al. 
confirmed this anti-inflammatory property by showing in mice that high galactosylation of IgG immune com-
plexes promotes the association of Fcγ RIIB and dectin-1, which blocks the pro-inflammatory effector functions 
of C5aR and CXCR226. Therefore, this would indicate that people with higher levels of immune activation would 
have more pro-inflammatory antibodies, as they have lower levels of IgG galactosylation.
In our study, the developing country-affluent country pattern and rural-urban pattern due to immune activa-
tion was most clear for IgG1 galactosylation, but was also seen for IgG2 and IgG4 subclasses. Furthermore, next 
to galactosylation, IgG sialylation and fucosylation were reduced for rural children. Although controversial for 
sialylation, both modifications might have anti-inflammatory effects. Sialylation was found to contribute to the 
beneficial effects of intravenous immunoglobulin (IVIg) treatment in some studies27,28, and afucosylated IgG1 was 
found to be a potent inducer of antibody-dependent cell-mediated cytotoxicity29–31. While the highest levels of 
sialylation were found in affluent countries and more urban communities, the number of sialic acids per galactose 
moiety (SA/Gal) were found to be highest in the more rural communities. This indicates separate regulation of 
sialylation and galactosylation, leading to smaller differences in sialylation between populations than for galac-
tosylation. Nevertheless, the overall reduced sialylation and fucosylation in rural children could strengthen the 
suggested pro-inflammatory effects of reduced galactosylation.
It could be speculated that IgG glycosylation adds another layer of control to avoid antibody-induced pathol-
ogy. Circulating antibodies could be kept in an anti-inflammatory state by certain glycosylation patterns, but 
upon danger and with the proper set of signals, more effective antibodies could be produced by switching to a 
more pro-inflammatory glycosylation profile. Therefore, the pro-inflammatory IgG glycosylation profile found 
in rural children might be better in fighting the higher infection pressure in the rural environment. In affluent 
countries, where infectious pressure is reduced, antibodies remain in their anti-inflammatory circulating state, 
with high levels of galactosylation. However, the switch to pro-inflammatory glycosylation might be aberrant 
in the case of autoimmune diseases, making IgG glycosylation a target for studies of disease mechanisms and 
therapeutics.
An interesting aspect of the degree of IgG1 galactosylation could be its use as a biomarker for immune activa-
tion. This study is one of the first comparing IgG glycosylation in various human populations, and shows the IgG1 
galactosylation pattern amongst various rural and urban populations. We have used plasma and serum samples 
collected with different protocols and stored for different periods of time, however, the same galactosylation pat-
tern is seen in each of the studied countries: lower galactosylation in communities where immune activation is 
higher due to higher exposure to microorganisms and parasites. Therefore, IgG galactosylation proves to be very 
stable, which is a prerequisite for a good biomarker. This also shows that, although genetics could explain some 
variation between countries, environmental factors have a strong effect32. Furthermore, IgG1 galactosylation, as a 
biomarker for immune activation, could be a valuable tool in studies examining infection pressure in developing 
countries or the prevalence of non-communicable inflammatory diseases in affluent regions of the world.
Methods
Study populations. School-aged children from Ecuador, Gabon, Germany, Ghana and the Netherlands 
were included in this study. Plasma or serum samples were obtained as part of other studies as described 
before12,33–38, and in accordance with guidelines approved by local medical ethical committees (Hospital Pedro 
Vicente Maldonado, Pichincha Province, Ecuador; International Foundation of the Albert Schweitzer Hospital, 
Lambaréné, Gabon; University of Münster, Münster, Germany; Ulm University, Ulm, Germany; Noguchi 
Memorial Institute for Medical Research Institutional Review Board, Accra, Ghana; Utrecht University Medical 
Center, Utrecht, the Netherlands) and written or thumb-printed informed consent of parents or legal guardians 
of the children. 193 plasma and serum samples came from a study conducted amongst rural Afro-Ecuadorian 
communities in Esmeraldas province, Ecuador, in 2005–200712. 39 samples were from a study conducted in the 
rural community of PK15 (PK) and semi-urban community of Lambaréné (LA) in Gabon in February 200533,34. 
49 samples were from a study conducted in 1995–1996 in urban Munich, southern Germany37. 149 samples were 
from a study in 2007 in rural areas around Ulm, southern Germany35. 323 serum samples came from a study 
conducted in Ghana, in two rural communities (AD and MA), an urban community with low socio-economic 
status (JT) and an urban community with high socio-economic status (UP), in 200338. 20 samples from the area 
of Utrecht in the Netherlands were collected in 2008–200936.
Gabonese and Ghanaian children were tested for STH infection, schistosomiasis and malaria. Ecuadorian 
children were tested for STHs only; schistosomiasis is not endemic. In Ghana, single samples were used for 
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parasitology38. 25 mg stool samples were used for the detection of hookworm, Ascaris lumbricoides (roundworm) 
and Trichuris trichiura (whipworm) by Kato-Katz method. 10 mL urine was filtered through a 10-mm-pore fil-
ter before detection of Schistosoma haematobium eggs by microscopy. Giemsa-stained thick-blood smears were 
used to detect malaria parasites by microscopy. In Gabon, stool samples were tested 1 or 2 times for A. lum-
bricoides and T. trichiura by Kato-Katz method33,34. Urine samples were tested 3 times for S. haematobium and 
an additional staining with ninhydrin solution was used. Malaria was determined by a single Giemsa-stained 
thick-blood smear. In Ecuador, single stool samples were used to detect hookworm, A. lumbricoides, T. trichiura, 
and Strongyloides stercoralis (threadworm) by modified Kato-Katz and formol–ether concentration methods39. 
German and Dutch children were not tested, as Germany and the Netherlands are not endemic for any of these 
parasitic infections.
Parent-reported asthma symptoms were known for German and Dutch children. Negative children were 
included in the main analysis; asthmatic children were only included for the comparison with healthy controls. 
No asthma data was available for the children from Ecuador, Gabon and Ghana. Body weight and height were 
determined for most children, from which age-standardised z-scores for body mass index (BMI) were calculated 
according the World Health Organisation Reference40. Furthermore, the communities in Ecuador have been 
extensively characterised by Rodriguez et al. to study the relationship between urbanisation and the prevalence 
of wheeze (Supplementary Table S6)12.
IgG glycosylation analysis. The glycosylation of IgG1, IgG2 and IgG4 was analysed in June and July 2012 
as described previously7,41. Briefly, the antibodies were captured from plasma/serum by affinity chromatography 
using Protein A beads. After tryptic digestion, the samples were analysed by fast nano reverse phase (RP) liq-
uid chromatography (LC) electrospray ionization (ESI) quadrupole time-of-flight (Q-TOF) mass spectrometry 
(MS). The datasets were internally calibrated using a list of known glycopeptides41 and processed with Bruker 
DataAnalysis 4.0, MS Align2, MZmine, Xtractor2D and Microsoft Excel 2010 software. Detected glycopeptides 
are listed in Supplementary Table S7.
To obtain the relative intensities of a total of 50 glycopeptide species from IgG1, IgG2, and IgG4, three iso-
topic peaks were integrated, summed, and normalised to the total subclass specific glycopeptide intensities. 
Subsequently, the level of galactosylation was calculated for IgG1 and IgG2 using the formula 0.5 × (G1F + G1F
N + G1FS + G1FNS + G1 + G1N + G1S + G1NS) + G2F + G2FN + G2FS + G2FNS + G2 + G2N + G2S + G2NS, 
and for IgG4 using 0.5 × (G1F + G1FN + G1FS + G1FNS) + G2F + G2FN + G2FS + G2FNS. In this formula, G is 
short for galactose, and is followed by a number indicating how many galactoses are present in the glycan (Fig. 1). 
The presence of fucose is indicated by F, of bisecting GlcNAc by N, and of sialic acid (N-acetylneuraminic acid) 
by S. The level of sialylation was calculated for IgG1 and IgG2 by G1FS + G2FS + G1FNS + G2FNS + G1S + G2
S + G1NS + G2NS and for IgG4 by G1FS + G2FS + G1FNS + G2FNS. The number of sialic acids per galactose 
moiety (SA/Gal) was determined by the level of IgG sialylation divided by 2× the level of galactosylation. The 
level of fucosylation was determined by G0F + G1F + G2F + G0FN + G1FN + G2FN + G1FS + G2FS + G1FNS 
+ G2FNS for IgG1 and IgG2 only, as afucosylated species of IgG4 remained below detection limit. The incidence 
of bisecting GlcNAc was calculated for IgG1 and IgG2 by G0FN + G1FN + G2FN + G1FNS + G2FNS + G0N + 
G1N + G2N + G1NS + G2NS and for IgG4 by G0FN + G1FN + G2FN + G1FNS + G2FNS.
C-reactive protein analysis. Plasma/serum CRP concentrations were measured in May 2013 as described 
before42 by sandwich enzyme-linked immunosorbent assay (ELISA) using 4000× diluted anti-human CRP IgG 
(The Binding Site, Birmingham, UK), 1000× diluted horseradish peroxidase-conjugated anti-human CRP IgG 
(AbD Serotec, Kidlington, UK), and the World Health Organisation (WHO) 1st international standard of human 
CRP (National Institute for Biological Standards and Control (NIBSC), Potters Bar, UK). Plasma/serum samples 
were diluted 200× (out of range samples were repeated diluted 100× or 2000× ). Substrate solution was 0.1 mg/
mL 3,3′ ,5,5′ -tetramethylbenzidine in citrate/phosphate buffer, pH 4.5. Plates were analysed by absorbance at 
450 nm with a reference wavelength of 490 nm using a Dynal plate reader (DYNEX Technologies, Worthing, UK).
Total IgE analysis. Plasma/serum total IgE concentrations were measured in March 2014 by ELISA. 
Maxisorp plates (Nunc, Roskilde, Denmark) were coated overnight with shaking with 1000× diluted polyclonal 
rabbit anti-human IgE capture antibody (Dako, Glostrup, Denmark) in 0.1 M sodium bicarbonate buffer, pH 
9.6, at 4 °C, and blocked with shaking for 1 h with 2% bovine serum albumin fraction V (Roche, Mannheim, 
Germany)/phosphate buffered saline at room temperature. Plates were then incubated with shaking for 1 h with 
100 μ L of 20× and 200× diluted plasma/serum samples and control samples at room temperature. The WHO 
3rd international standard of human serum IgE (NIBSC) was applied at a 10-step 2× serial dilution starting at 
200 ng/mL. After washing, the plates were incubated with shaking for 1 h with 1000× diluted biotinylated goat 
anti-human IgE, ε -chain specific, detection antibody (Vector Laboratories, Burlingame, CA, USA) followed by 
3000× diluted streptavidin-alkaline phosphatase conjugate (Roche) for 1 h at room temperature, and by 100 μ L 
1 mg/mL p-nitrophenylphosphate substrate (Roche) in 0.1 M diethylanolamine buffer for 25 min. The reaction 
was stopped by 100 μ L 3 M NaOH and absorbance was measured at 405 nm. The detection limit was 4.0 ng/mL.
Statistical analysis. Data analysis was performed using IBM SPSS Statistics version 20 for Windows 
(IBM Corp., Armonk, NY, USA). Graphs were made using GraphPad Prism version 6 for Windows (GraphPad 
Software, San Diego, CA, USA). CRP and total IgE levels were log10 transformed for statistical analyses. 
Spearman’s correlation was used to assess various associations with IgG galactosylation at the level of individuals, 
except for correlations with infrastructure, socioeconomic and lifestyle factors in Ecuador, which were performed 
at the community level. Comparisons of IgG1 galactosylation between countries and communities were per-
formed with the non-parametric Kruskal-Wallis H test, followed by Dunn-Bonferroni post-hoc test, or Mann 
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Whitney U test. Random-intercept fixed-slope linear mixed (multi-level) modelling was used to describe the gly-
cosylation differences considering all communities, irrespective of country. Linear mixed models are extensions 
of linear regression, where fixed effects are comparable to conventional linear regression and random effects are 
introduced to take into account cluster effects, in this case the various communities, by estimating an intercept 
for each community. The starting model contained age, sex, CRP level, total IgE level, schistosomiasis status and 
STH infection status as fixed effects. Ecuadorian children were assumed negative for schistosomiasis. Dutch and 
German children were assumed negative for schistosomiasis and STH infection. The variance component for 
communities was significant according to the associated likelihood ratio test (P < 0.001). Therefore, communities 
were kept in the model as a random effect. Subsequently, a top-down modelling strategy was used as described by 
West et al.43 to remove non-significant fixed factors and to reach the final model as shown in Table 2. (Two-tailed) 
P values below .05 were considered statistically significant.
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